Showing results (261-270 of 293) with videos related to
Sort By:
Pageof 30
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 24, 2013
Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trialBryan P Schneider, Robert J Gray, Milan Radovich, et al.NPJ Breast Cancer|September 2, 2022
Assessment of MRI to estimate metastatic dissemination risk and prometastatic effects of chemotherapyGeorge S Karagiannis, Anthony Bianchi, Luis Rivera Sanchez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast CancerKeith L Knutson, Hala Abu-Fares, Patricia Keating, et al.JAMA Network Open|May 10, 2022
Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112)Soudabeh Fazeli, Bradley S Snyder, Ilana F Gareen, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2020
Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORxLynne I Wagner, Robert J Gray, Joseph A Sparano, et al.Blood|September 10, 2013
Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patientsStefan K Barta, Xiaonan Xue, Dan Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2015
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105Melinda L Telli, Kristin C Jensen, Shaveta Vinayak, et al.JAMA Oncology|January 18, 2019
Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ TreatmentConstance D Lehman, Constantine Gatsonis, Justin Romanoff, et al.NPJ Breast Cancer|July 20, 2017
Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trialKerin Adelson, Bhuvaneswari Ramaswamy, Joseph A Sparano, et al.Radiology|April 1, 2025
MRI-based Radiomic Features for Risk Stratification of Ductal Carcinoma in Situ in a Multicenter Setting (ECOG-ACRIN E4112 Trial)Kalina P Slavkova, Ruya Kang, Anum S Kazerouni, et al.Pageof 30